Erasca, Inc. (ERAS) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The HERKULES-3 trial, officially titled “A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Gastrointestinal Malignancies,” tests Erasca, Inc.’s ERAS-007 in hard-to-treat colorectal and pancreatic cancers. The study aims to find a safe dose, assess early tumor response, and gauge how this targeted approach might fit into future treatment options.
The study evaluates ERAS-007, an oral targeted cancer drug designed to block a key growth pathway in tumors. It is given in combination with approved drugs encorafenib and cetuximab, or with palbociclib, to see if double or triple drug regimens can improve outcomes in advanced gastrointestinal cancers.
HERKULES-3 is an interventional, Phase 1b/2 trial with a non-randomized, stepwise design. Patients are assigned to dose escalation or expansion cohorts without blinding, and the main goal is treatment focused, aiming to determine safe dose levels and early signs of benefit rather than to compare against a control arm.
The trial began after submission on September 1, 2021, moving from initial dose finding into larger expansion as safety data emerged. The study is now listed as completed, with a key update filed on March 23, 2026, signaling that follow-up and data cleaning are mature enough to support upcoming disclosures or presentations.
The latest update matters for investors because completion of a multi-drug, targeted oncology study is a key value inflection point for Erasca (ERAS). Positive safety and activity data versus current standards could boost confidence in ERAS-007 and support the company’s positioning against larger oncology players such as Pfizer (palbociclib), Pierre Fabre/Array (encorafenib), and Eli Lilly (cetuximab), while weak data may pressure the stock and raise questions on the broader MAPK strategy.
With HERKULES-3 now marked as completed and recently updated on the registry, investors should watch for top-line data and conference readouts as near-term catalysts, with further details available on the ClinicalTrials portal.
To learn more about ERAS’s potential, visit the Erasca, Inc. drug pipeline page.